167262-92-2

Usage

Molecular structure

Piperidine derivative with a BOC protecting group, a cyano group, and a pyridinyl group attached to the piperidine ring

Functional groups

BOC (tert-butyloxycarbonyl), cyano (-CN), and pyridinyl (C5H4N)

Appearance

Unknown, but likely a solid or crystalline substance

Solubility

Unknown, but may be soluble in organic solvents like methanol, ethanol, or acetone

Stability

Stable under normal conditions, but sensitive to hydrolysis or other reactions that could remove the BOC protecting group

Reactivity

Reacts with various reagents to form new compounds, particularly in organic synthesis and pharmaceutical applications

Applications

Building block in organic synthesis, used in the pharmaceutical industry for drug production, and as a research chemical for developing new compounds with potential pharmacological activities

Importance

Versatile compound in organic chemistry and drug discovery, contributing to the development of various drugs and pharmaceuticals

Safety

Potential hazards and safety precautions not provided, but should be handled with care due to its reactivity and potential use in pharmaceuticals

Upstream product

• 626-61-9 4-Chloropyridine 
• 91419-52-2 1-tert-butoxycarbonyl-4-cyanopiperidine 
• 694-52-0 4-fluoropyridine 
• 65520-12-9 4-cyanopyridine hydrochloride 
• 118753-70-1 N-(tert-butyloxycarbonyl)bis(2-chloroethyl)amine 
• 13121-99-8 pyridin-4-ylacetonitrile 

Relevant academic research and scientific papers

Preparation of 4-heteroaryl-4-cyanopiperidines via SNAr substitution reactions

The scope and limitations of SNAr substitution reactions of metalated 4-cyanopiperidines with heterocyclic halides were explored. These facile reactions provide rapid access to a wide range of 4-heteroaryl-4-cyanopiperidines and have resulted i

Discovery of N-{[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamides as novel, selective and potent GlyT1 inhibitors

Employing an iterative analogue library approach, novel potent and selective glycine transporter 1 (GlyT1) inhibitors containing a 4-pyridin-2-ylpiperidine sulfonamide have been discovered. These inhibitors are devoid of time-dependent CYP inhibition activity and exhibit improved aqueous solubility versus the corresponding 4-phenylpiperidine analogues.

THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS

The invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof. The formula I thiazolyl compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's disease

SUBSTITUTED PYRROLIDIN-3-YL-ALKYL-PIPERIDINES

The present invention relates to substituted pyrrolidinyl-3-yl-alkyl-piperidines, their stereoisomers, and pharmaceutically acceptable salts thereof and processes for preparation of the same. The compounds of the present invention are useful in their pharmacological activities such as tachykinin antagonism, especially substance P and neurokinin A antagonism, and the like. Compounds having the property of tachykinin antagonism are indicated for conditions associated with neurogenic inflammation and other diseases described herein.